XLC ALMADA WORKE

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=DctOTiwXfFs

Eduardo Dunayevich, MD, Vice President, VMAT2 Franchise Leader, and Clinical Business Development Leader for Neurocrine Biosciences, Inc. discusses an involuntary movement disorder called tardive dyskinesia (TD) which is associated with prolonged use of certain mental health medicines (antipsychotics) that are used to treat depression, bipolar disorder, schizophrenia, and schizoaffective disorder. He talks about the symptoms of TD; the physical, emotional, and social impact of TD; and the importance of increasing awareness of TD, including the importance of regular screenings with a healthcare provider. For more information visit TalkAboutTD.com • • #TardiveDyskinesia • • Eduardo Dunayevich, M.D. serves as the Vice President, VMAT2 Franchise Leader, and Clinical Business Development Leader for Neurocrine Biosciences, a position he has held since June 2021. Dr. Dunayevich has held numerous positions in biotech as the Vice President and Head of Clinical Sciences of Greenwich Biosciences, Executive Vice President and Chief Medical Officer of Annexon Bioscience, Executive Director/Vice President and Global Product Lead for the CNS Therapeutic Area Unit at Takeda Pharmaceuticals, Executive Director and Global Development Leader for Neuroscience at Amgen Inc., Chief Medical Officer at Orexigen Therapeutics Inc., and Medical Advisor/Associate Medical Director at Lilly Neuroscience. He studied at the University of Buenos Aires Medical School and completed his psychiatry residency training at the University of Cincinnati Medical Center in Ohio where he was also a faculty member. Dr. Dunayevich has also been published in numerous peer-reviewed medical journals including The Journal of the American Medical Association, Lancet, Obesity, Schizophrenia Bulletin and Neuropsychopharmacology.

#############################

New on site